Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

Interim surveillance network data showed lower hospitalization rates following the availability of prevention products.

In a recent study of a population of infants, published online May 6 in Pediatrics, 72% of infants were found to be immunized ...

Maternal RSV vaccination and nirsevimab were associated with a reduction in RSV hospitalization rates in infants aged 0 to 7 months during the 2024-2025 RSV season.

New findings provide compelling evidence for the protective benefits of maternal RSVpreF vaccination during pregnancy.

New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the ...

Here's what RSV is, why it especially impacts the youngest and oldest members of society and how it is usually treated.

The number of COVID-19 infections in China has been steadily rising since early April, but the overall spread of acute ...

In a recent study of a population of infants, 72% of infants were found to be immunized against respiratory syncytial virus.

Maternal RSV vaccination and nirsevimab were associated with a reduction in hospitalization rates among infants aged 0 to 7 months.

TUESDAY, May 6, 2025 (HealthDay News) -- In a recent study of a population of infants, published online May 6 in Pediatrics, ...

New multi-center US study finds RSV co-infection in children under two is not linked to worse clinical outcomes, challenging ...